

FOI 2639

3rd October '24

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Request:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Response:

| |
|--------------------------------------|
| Abatacept [Orencia] - 89 |
| Adalimumab [Humira] - 36 |
| Adalimumab Biosimilars – 550 |
| Apremilast [Otezla] - 1 |
| Baricitinib [Olumiant] - 43 |
| Bimekizumab [Bimzelx] - 2 |
| Certolizumab [Cimzia] - 75 |
| Etanercept [Enbrel] - 10 |
| Etanercept Biosimilars - 211 |
| Filgotinib [Jyseleca] - 0 |
| Golimumab [Simponi] - 78 |
| Guselkumab [Tremfya] - 14 |
| Infliximab [Remicade] - 1 |
| Infliximab Biosimilars - 29 |
| Ixekizumab [Taltz] - 54 |
| Risankizumab [Skyrizi] - 1 |
| Rituximab [MabThera] - 0 |
| Rituximab Biosimilars - 121 |
| Sarilumab [Kevzara] - 19 |
| Secukinumab [Cosentyx] - 147 |
| Tocilizumab [Ro Actemra] - 43 |
| Tocilizumab Biosimilars - 7 |
| Tofacitinib [Xeljanz] - 8 |
| Upadacitinib [Rinvoq] - 26 |
| Ustekinumab [Stelara] - 0 |
| Ustekinumab Biosimilar - 0 |

Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

Response:

| |
|-------------------------------------|
| Adalimumab [Humira] - 15 |
| Adalimumab Biosimilars - 172 |
| Certolizumab [Cimzia] - 24 |
| Etanercept [Enbrel] - 0 |
| Etanercept Biosimilars - 36 |
| Golimumab [Simponi] - 33 |
| Infliximab [Remicade] - 0 |
| Infliximab Biosimilars - 7 |
| Ixekizumab [Taltz] - 12 |
| Secukinumab [Cosentyx] - 57 |
| Tofacitinib [Xeljanz] - 0 |
| Upadacitinib [Rinvoq] - 4 |

Email: Foi.Team@Southerntrust.hscni.net